Navigation Links
Neurochem reports results for third quarter of fiscal 2007
Date:11/7/2007

000 for the nine-month period), compared to $388,000 for the corresponding period in the previous year ($1,292,000 for the nine-month period). Research tax credits represent refundable tax credits earned under the Quebec Scientific Research and Experimental Development Program for expenditures incurred in Quebec.

Other research and development charges amounted to nil for the current quarter and nine-month period, compared to $1,127,000 for the quarter and nine-month period ended September 30, 2006. In 2006, the Quebec taxation authorities confirmed their position in the application of the tax credit program that denied tax credits on research and development taxable benefits relating to stock options for 2005 and prior years. Accordingly, management determined at that time that the criteria for recognition of these credits were no longer met and recorded a provision for these research tax credits.

General and administrative expenses totaled $2,559,000 for the current quarter ($9,184,000 for the nine-month period), compared to $2,723,000 for the same quarter in the previous year ($8,703,000 for the nine-month period). These costs are incurred to support the overall activities of the Company.

Arbitral award amounted to nil for the current quarter and nine-month period compared to nil for the quarter ended September 30, 2006 and $1,835,000 for the nine-month period ended September 30, 2006. This expense related to the dispute with Immtech Pharmaceuticals, Inc. (formerly known as Immtech International, Inc. (Immtech)), which came to a conclusion in January 2007 when Immtech, the University of North Carolina at Chapel Hill (UNC), and Georgia State University Research Foundation, Inc. filed with the Federal District Court for the Southern District of New York, U.S.A. a Notice of Voluntary Dismissal. The plaintiffs voluntarily dismissed their complaint against Neurochem in the Federal District Court without any payment, license, business agreement, conces
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Nashville, TN (PRWEB) May 20, 2013 Along ... Warren Melamed has remained a fervent proponent of regular ... appropriate brushing and flossing twice a day. While these recommendations ... of tooth decay reveal that most adults and children are ... patients must find a new way to break into the ...
(Date:5/20/2013)... Senior Solutions Management Group (SSMG), a ... Southeast, today announced that four of its Resident Assistants ... communities have received The Caring Heart Award from Alzheimer’s ... Loudon, Nicole Braden from River Oaks Place in Loudon, ... and Meghan McCormick from Wellspring Senior Living in Knoxville ...
(Date:5/20/2013)... 2013 The main objective for the present ... into a single comprehensive report. The objective was to ... this industry. Thus, it is timely to examine the ... an urgent need in the life science industry for technologies ... in a high-throughput, multiplex and low-cost way. Proteomic technologies ...
(Date:5/20/2013)... Idol lash has designed its brand new ... eyelashes in a matter of few weeks. It is completely ... an extra pack offer to help more women achieve broad ... on the Idol lash official website. , Numerous trials were ... density up to 82% in just a few weeks. According ...
(Date:5/20/2013)... The Semi Truck Accident Victims ... free service for an innocent victim of a catastrophic ... state our services are unparalleled. What this means is ... victim of a passenger vehicle involved in a semi ... Virginia, Ohio, New Jersey, Indiana, Maryland, Georgia, Nebraska, Kansas, ...
Breaking Medicine News(10 mins):Health News:New AirFloss Product Offers Oral Hygiene Innovation, Dental Professional Warren Melamed Comments 2Health News:Senior Solutions Management Caregivers Receive Caring Heart Award From Alzheimer’s Tennessee 2Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 2Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 3Health News:Idol Lash Eyelash Growth Enhancer Now Offered Extra Pack for Limited Time Only at HealthCareSupplementz.com 2Health News:Semi Truck Accident Victims Center Urges Family Members Of Victims Injured In A Horrific Semi Truck Accident In Any US State To Call Them First For An Unsurpassed Response 2
... swallowing the mobile phone by a 24 year women was an ... // The Blue Spring Police are investigated the incident in which ... phone during an argument with her boy friend in which she ... friend. Police got a phone call from her boyfriend that her ...
... Hewitt, the Health Secretary of the UK has imposed a ... //This move has raised doubts as to whether the private ... the NHS will be put into operation. ,The ... ?1 billion plan has been questioned by Ms Hewitt. The ...
... erythematosus (lupus) is a disease in which the body's ... the skin, joints and internal organs.// A study has ... take oral contraceptives safely without any complications like increased ... that characterize the disease. ,The study was ...
... scanner has been developed for premature and newborn babies that ... how the baby brain is working. ,Currently, there are ... Magnetic resonance imaging (MRI) can provide data on brain ... of risk. ,The alternative, ultrasound, can be performed ...
... health benefits of milk thistle, an herbal remedy employed in ... recent study highlighting the lack of evidence for its safety ... for thistle milk, with over 1 million people suffering from ... worldwide. ,The research team analyzed the results of ...
... been passed by the Food and Drug Administration (FDA) saying that ... to be mentioned in the label of the product. ... milk, eggs, fish, crustaceans, wheat, tree nuts, soybeans and peanuts. ... allergies are one of the major causes of death in US. ...
Cached Medicine News:Health News:Milk Thistle Not An Effective Cure For Liver Disease 2
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com ... today that the United States Food and Drug Administration ... for ORMD-0801, its oral insulin capsule. "We ... proceed," stated Nadav Kidron , CEO ... for Oramed and we look forward to continuing to ...
(Date:5/16/2013)... Ill. and MECHELEN, Belgium ... GLPG) and AbbVie (NYSE: ABBV ) announced ... to include Crohn,s disease.  Galapagos will fund and complete ... designed to facilitate rapid progression into Phase 3.  Upon ... AbbVie will pay Galapagos $50 million.  The terms of ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... of Regulatory Submissions Leadership Strengthened with Clinical ... Trials Services and Standards-Based Data Management, WHIPPANY, ... (ISI) announced today it agreed to terms to ... industry moving to,standards-based regulatory submissions, the acquisition further ...
... the First Hsp90 Inhibitor to Enter Registration Trials, ... KOSN ) today announced that it has successfully,reached a ... on the design of its TIME-1 clinical trial, a ... a treatment for patients with,multiple myeloma. Through the FDA,s ...
Cached Medicine Technology:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: